Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Dr. Reddy’s Teraleve® Fesoterodine Fumarate Prolonged-Release tablets for incontinence

Dr. Reddy’s Teraleve ® 4mg and 8mg Fesoterodine Fumarate Prolonged-Release tablets have been available in the UK since their launch on 1st June 2022.

Therapeutic indications:


  • Indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder syndrome.

Presentation:

4mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the number ‘4’.

8mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the number ‘8’.

Tablets are packaged in aluminium-aluminium blisters in a carton with a PIL.

Product NameStrengthPack SizePIP CodeEAN No.Legal Category
Teraleve® Fesoterodine Fumarate Prolonged-Release Tablets4mg28125-69245036072008328POM
Teraleve® Fesoterodine Fumarate Prolonged-Release Tablets8mg28125-69325036072008311POM

Teraleve® Fesoterodine Fumarate Prolonged-Release tablets are available from your local wholesaler or by contacting Dr.Reddy’s on 01223 651475 or customerserviceuk@drreddys.com.

Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: https://www.medicines.org.uk.  Prescribers are recommended to consult the summary of product characteristics before prescribing - SmPC.